EP1.04-10 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
نویسندگان
چکیده
منابع مشابه
A review of the role of dopamine receptors and novel therapeutic strategies in non-small cell lung cancer (NSCLC)
Lung cancer is a very aggressive and most deadly cancer in both men and women. Lung cancer is divided into two types of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is divided into 3 subgroups: adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large cell carcinoma (LCC). Dopamine is involved in controlling motions, cognition, emotions, memory and reward mech...
متن کاملphase ii study of gemcitabine and cisplatin regimen in advanced non-small cell lung cancer (nsclc).
background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...
متن کامل[Non-small cell lung cancer (NSCLC)].
The goal of radiation therapy for non-small cell lung cancer (NSCLC) is to improve the survival rate of patients without increasing treatment-related toxicity and to improve patients' quality of life. Several prospective randomized trials have demonstrated a survival advantage in combined modality treatment over radiotherapy or chemotherapy alone when a cisplatin-based chemotherapy regimen is u...
متن کاملNivolumab in Metastatic Non–Small Cell Lung Cancer
Author's disclosures of potential conflicts of interest are found at the end of this article. L ung cancer is the leading cause of cancer deaths in the United States (Ameri-can Cancer Society [ACS], 2015). Non–small cell lung cancer (NSCLC) is one of the most common types of the disease and accounts for 85% to 90% of lung cancer cases (ACS, 2015). Nonsquamous NSCLC accounts for approximately 45...
متن کاملEGFR mutation testing in non-small cell lung cancer (NSCLC).
Lung carcinoma is subdivided into small cell carcinoma and non-small cell carcinoma (NSCLC). NSCLC is heterogeneous group of carcinomas and accounts for 70-80% of lung cancer. NSCLC is further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been cha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2019
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.08.2140